- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02622698
Oral Protein Supplementation Following Non-bariatric Surgery
December 2, 2015 updated by: Christina Riojas, Eisenhower Army Medical Center
A Randomized Trial of Oral Protein Supplementation Following Non-bariatric Abdominal Surgery
Investigators performed a randomized controlled trial of 62 patients undergoing elective abdominal operations.
The treatment group was provided a liquid protein supplement and instructed to take a dose three times daily for the first 20 postoperative days.
Investigators followed patients for six months and compared wound healing and changes in weight and laboratory values.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients scheduled to undergo abdominal surgery [cholecystectomy, ventral hernia repair, colectomy, non-bariatric gastric surgery, appendectomy, small bowel resection, lysis of adhesions, liver resection, splenectomy, proctectomy, stoma construction, pancreatic surgery, duodenal surgery, adrenal surgery, renal surgery, or cystectomy]
Exclusion Criteria:
- Age less than 18 years
- Pregnant
- Abdominal surgery within the past 6 months
- Inability to attend follow-up appointments for at least 6 months
- Liver failure (Child-Pugh Class B or C) or kidney failure (glomerular filtration rate (GFR) less than 30).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
The patients in the control group did not receive any supplementation, and were directed to follow the dietary guidelines of their surgeon.
|
Placebo- Patients did not take any protein supplementation after surgery
Other Names:
|
Experimental: Treatment
Patients were instructed to consume one ounce (containing 16 grams of protein) of the supplement three times daily.
No other modifications were made to the patient's diet.
Patients were provided with a total of 60 doses, which would last 20 days if they consumed each dose as instructed.
|
Prostat AWC- patients received protein supplementation after surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in weight
Time Frame: Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Mean preoperative weight compared to mean postoperative weight at each follow-up appointment.
Weight recorded in pounds, subsequent measurements at each postoperative point were normalized to the preoperative weight and reported as a relative percentage of the preoperative weight.
|
Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound healing
Time Frame: Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Overall wound healing was documented on a scale of 0-2 (0 for unhealed, 1 for partially healed, 2 for completely healed).
A wound was considered partially healed if there was any portion of the wound which had epidermal edges that were not in direct contact.
|
Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in white blood cell count (1x10 3/ uL)
Time Frame: Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in white blood cell count relative to preoperative white blood cell count, calculated as absolute change
|
Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in total protein (g/ dL)
Time Frame: Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in total protein at each follow-up point relative to preoperative total protein, calculated as absolute change
|
Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in albumin (g/ dL)
Time Frame: Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in albumin at each follow-up point relative to preoperative albumin, calculated as absolute change
|
Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in prealbumin (mg/ dL)
Time Frame: Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Change in prealbumin at each follow-up point relative to preoperative prealbumin, calculated as absolute change
|
Preoperative, and then postoperative at 1-2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
December 1, 2015
First Submitted That Met QC Criteria
December 2, 2015
First Posted (Estimate)
December 4, 2015
Study Record Updates
Last Update Posted (Estimate)
December 4, 2015
Last Update Submitted That Met QC Criteria
December 2, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- 356154
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Protein Supplementation
-
Alexandria UniversityRecruitingProtein SupplementationEgypt
-
Bettery S.A.CompletedProtein SupplementationPortugal
-
Cardinal Tien HospitalCompletedProtein Supplementation | Exercise InterventionTaiwan
-
University of AarhusCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento... and other collaboratorsCompletedProtein Supplementation | Sports NutritionBrazil
-
Poznan University of Physical EducationNational Science Centre, Poland; Faculty of Physical Education and Sport at... and other collaboratorsRecruitingSupplementation | Sport | Sports Nutrition | Sports Dietetics | Protein Kinases | Aerobic Capacity | Fat Free MassCzechia, Poland
-
Universidad Católica San Antonio de MurciaCompleted
-
University of CadizCompletedPlacebo | Cold-water Immersion | Protein-carbohydrates Supplementation | Active RecoverySpain
-
California Baptist UniversityCompletedDietary SupplementationUnited States
-
Poznan University of Life SciencesNational Science Centre, PolandUnknown
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States